These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

357 related articles for article (PubMed ID: 31095314)

  • 1. Diagnostic performance of 18F-fluciclovine PET/CT for regional lymph node metastases in patients with primary prostate cancer: a multicenter phase II clinical trial.
    Suzuki H; Jinnouchi S; Kaji Y; Kishida T; Kinoshita H; Yamaguchi S; Tobe T; Okamura T; Kawakita M; Furukawa J; Otaka A; Kakehi Y
    Jpn J Clin Oncol; 2019 Sep; 49(9):803-811. PubMed ID: 31095314
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Diagnostic accuracy of 18F-fluciclovine PET/CT in primary lymph node staging of prostate cancer.
    Hoekstra RJ; Beulens A; Vrijhof EHJEJ; Wyndaele DNJ; Roef M; Brouwer LJM; Somford DM; Sedelaar M; van Basten JA
    Nucl Med Commun; 2021 May; 42(5):476-481. PubMed ID: 33323869
    [TBL] [Abstract][Full Text] [Related]  

  • 3.
    Selnæs KM; Krüger-Stokke B; Elschot M; Willoch F; Størkersen Ø; Sandsmark E; Moestue SA; Tessem MB; Halvorsen D; Kjøbli E; Angelsen A; Langørgen S; Bertilsson H; Bathen TF
    Eur Radiol; 2018 Aug; 28(8):3151-3159. PubMed ID: 29294158
    [TBL] [Abstract][Full Text] [Related]  

  • 4. More advantages in detecting bone and soft tissue metastases from prostate cancer using
    Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
    Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Diagnostic performance and safety of NMK36 (trans-1-amino-3-[18F]fluorocyclobutanecarboxylic acid)-PET/CT in primary prostate cancer: multicenter Phase IIb clinical trial.
    Suzuki H; Inoue Y; Fujimoto H; Yonese J; Tanabe K; Fukasawa S; Inoue T; Saito S; Ueno M; Otaka A
    Jpn J Clin Oncol; 2016 Feb; 46(2):152-62. PubMed ID: 26732384
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Reader Training for the Restaging of Biochemically Recurrent Prostate Cancer Using
    Miller MP; Kostakoglu L; Pryma D; Yu JQ; Chau A; Perlman E; Clarke B; Rosen D; Ward P
    J Nucl Med; 2017 Oct; 58(10):1596-1602. PubMed ID: 28385791
    [No Abstract]   [Full Text] [Related]  

  • 7. Comparison of Diagnostic Utility of Fluciclovine PET/CT Versus Pelvic Multiparametric MRI for Prostate Cancer in the Pelvis in the Setting of Rising PSA After Initial Treatment.
    Chen B; Bathala TK; Xu G; Teyateeti A; Chapin BF; Tang C; Tu SM; Macapinlac HA; Lu Y
    Clin Nucl Med; 2020 May; 45(5):349-355. PubMed ID: 31977495
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Image Guided Planning for Prostate Carcinomas With Incorporation of Anti-3-[18F]FACBC (Fluciclovine) Positron Emission Tomography: Workflow and Initial Findings From a Randomized Trial.
    Schreibmann E; Schuster DM; Rossi PJ; Shelton J; Cooper S; Jani AB
    Int J Radiat Oncol Biol Phys; 2016 Sep; 96(1):206-13. PubMed ID: 27511856
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Recurrent prostate cancer detection with anti-3-[(18)F]FACBC PET/CT: comparison with CT.
    Odewole OA; Tade FI; Nieh PT; Savir-Baruch B; Jani AB; Master VA; Rossi PJ; Halkar RK; Osunkoya AO; Akin-Akintayo O; Zhang C; Chen Z; Goodman MM; Schuster DM
    Eur J Nucl Med Mol Imaging; 2016 Sep; 43(10):1773-83. PubMed ID: 27091135
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [
    Alemozaffar M; Akintayo AA; Abiodun-Ojo OA; Patil D; Saeed F; Huang Y; Osunkoya AO; Goodman MM; Sanda M; Schuster DM
    J Urol; 2020 Oct; 204(4):734-740. PubMed ID: 32347780
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of 18F-Fluciclovine PET/CT and 99mTc-MDP bone scan in detection of bone metastasis in prostate cancer.
    Chen B; Wei P; Macapinlac HA; Lu Y
    Nucl Med Commun; 2019 Sep; 40(9):940-946. PubMed ID: 31343613
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Multisite Experience of the Safety, Detection Rate and Diagnostic Performance of Fluciclovine (
    Bach-Gansmo T; Nanni C; Nieh PT; Zanoni L; Bogsrud TV; Sletten H; Korsan KA; Kieboom J; Tade FI; Odewole O; Chau A; Ward P; Goodman MM; Fanti S; Schuster DM; Willoch F
    J Urol; 2017 Mar; 197(3 Pt 1):676-683. PubMed ID: 27746282
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A Prospective Head-to-Head Comparison of 18F-Fluciclovine With 68Ga-PSMA-11 in Biochemical Recurrence of Prostate Cancer in PET/CT.
    Pernthaler B; Kulnik R; Gstettner C; Salamon S; Aigner RM; Kvaternik H
    Clin Nucl Med; 2019 Oct; 44(10):e566-e573. PubMed ID: 31283605
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Is There Any Role for 18F-Fluciclovine PET/CT in the Presence of Undetectable PSA in Prostate Cancer Patients After Definitive Treatment?
    Teyateeti A; Teyateeti A; Macapinlac HA; Lu Y
    Clin Nucl Med; 2020 Sep; 45(9):672-678. PubMed ID: 32604105
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Initial Institutional Experience with 18F-Fluciclovine PET-CT in Biochemical Recurrence of Prostate Cancer.
    Farkas AB; Green ED; Thaggard AL; Vijayakumar V; Henegan JC; Lirette ST; Nittala MR; Vijayakumar S
    South Med J; 2021 Nov; 114(11):703-707. PubMed ID: 34729614
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [
    Zanoni L; Bianchi L; Nanni C; Pultrone C; Giunchi F; Bossert I; Matti A; Schiavina R; Fiorentino M; Romagnoli D; Fonti C; Lodi F; D'Errico A; Brunocilla E; Porreca A; Fanti S
    Eur J Nucl Med Mol Imaging; 2021 Dec; 49(1):390-409. PubMed ID: 34213609
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Initial Results of a Prospective Clinical Trial of 18F-Fluciclovine PET/CT in Newly Diagnosed Invasive Ductal and Invasive Lobular Breast Cancers.
    Ulaner GA; Goldman DA; Gönen M; Pham H; Castillo R; Lyashchenko SK; Lewis JS; Dang C
    J Nucl Med; 2016 Sep; 57(9):1350-6. PubMed ID: 26940766
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [18F]fluoromethylcholine (FCH) positron emission tomography/computed tomography (PET/CT) for lymph node staging of prostate cancer: a prospective study of 210 patients.
    Poulsen MH; Bouchelouche K; Høilund-Carlsen PF; Petersen H; Gerke O; Steffansen SI; Marcussen N; Svolgaard N; Vach W; Geertsen U; Walter S
    BJU Int; 2012 Dec; 110(11):1666-71. PubMed ID: 22520686
    [TBL] [Abstract][Full Text] [Related]  

  • 19. (18)F-FACBC (anti1-amino-3-(18)F-fluorocyclobutane-1-carboxylic acid) versus (11)C-choline PET/CT in prostate cancer relapse: results of a prospective trial.
    Nanni C; Zanoni L; Pultrone C; Schiavina R; Brunocilla E; Lodi F; Malizia C; Ferrari M; Rigatti P; Fonti C; Martorana G; Fanti S
    Eur J Nucl Med Mol Imaging; 2016 Aug; 43(9):1601-10. PubMed ID: 26960562
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The role of
    Kim SJ; Lee SW
    Clin Radiol; 2019 Nov; 74(11):886-892. PubMed ID: 31358294
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.